Neuroactive peptides as putative mediators of antiepileptic ketogenic diets

Carmela Giordano¹, Maddalena Marchiò¹,²,³, Elena Timofeeva⁴ and Giuseppe Biagini¹,² *

¹ Laboratory of Experimental Epileptology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
² Neuropediatric Unit, Department of Medical and Surgical Sciences for Children and Adults, Policlínico Hospital, University of Modena and Reggio Emilia, Modena, Italy
³ Department of Neurosciences, NOCSAE Hospital, Modena, Italy
⁴ Département Psychiatrie et Neurosciences, Faculté de Médecine, Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada

Edited by:
Cara Jean Westmark, University of Wisconsin, USA

Reviewed by:
Richard Eugene Frye, Children’s Hospital Boston, USA; Harvard University, USA
David Ruskin, Trinity College, USA

*Correspondence:
Giuseppe Biagini, Laboratorio di Epilettologia Sperimentale, Sezione di Fisiologia e Neuroscienze, Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università di Modena e Reggio Emilia, Via Campi 287, Modena 41125, Italy
e-mail: gbiagini@unimore.it

Various ketogenic diet (KD) therapies, including classic KD, medium chain triglyceride administration, low glycemic index treatment, and a modified Atkins diet, have been suggested as useful in patients affected by pharmacoresistant epilepsy. A common goal of these approaches is to achieve an adequate decrease in the plasma glucose level combined with ketogenesis, in order to mimic the metabolic state of fasting. Although several metabolic hypotheses have been advanced to explain the anticonvulsant effect of KDs, including changes in the plasma levels of ketone bodies, polyunsaturated fatty acids, and brain pH, direct modulation of neurotransmitter release, especially purinergic (i.e., adenosine) and γ-aminobutyric acidergic neurotransmission, was also postulated. Neuropeptides and peptide hormones are potent modulators of synaptic activity, and their levels are regulated by metabolic states. This is the case for neuroactive peptides such as neuropeptide Y, galanin, cholecystokinin, and peptide hormones such as leptin, adiponectin, and growth hormone-releasing peptides (GHRPs). In particular, the GHRP ghrelin and its related peptide des-acyl ghrelin are well-known controllers of energy homeostasis, food intake, and lipid metabolism. Notably, ghrelin has also been shown to regulate the neuronal excitability and epileptic activation of neuronal networks. Several lines of evidence suggest that GHRPs are upregulated in response to starvation and, particularly, in patients affected by anorexia and cachexia, all conditions in which also ketone bodies are upregulated. Moreover, starvation and anorexia nervosa are accompanied by changes in other peptide hormones such as adiponectin, which has received less attention. Adipocytokines such as adiponectin have also been involved in modulating epileptic activity. Thus, neuroactive peptides whose plasma levels and activity change in the presence of ketogenesis might be potential candidates for elucidating the neurohormonal mechanisms involved in the beneficial effects of KDs. In this review, we summarize the current evidence for altered regulation of the synthesis of neuropeptides and peripheral hormones in response to KDs, and we try to define a possible role for specific neuroactive peptides in mediating the antiepileptic properties of diet-induced ketogenesis.

Keywords: adiponectin, fasting, ghrelin, ketogenic diet, neuropeptide Y, epilepsy

The lack of a satisfactory response to pharmacological therapy in patients affected by epilepsy is a major neurological problem. In addition, in patients affected by epilepsy, antiepileptic drugs (AEDs) may induce serious side effects. Finding a solution to pharmacoresistance has been recently recognized as a priority by clinicians, parents, and stakeholders (1). Although various new AEDs are available to address refractory epilepsy, no improvements in treating drug resistance have been obtained, even with the release of additional new drugs (2). Alternatively to drug therapy, pharmacoresistant patients could be eligible for treatments such as: (i) neurosurgical resection of epileptic foci, (ii) intracranial or extracranial neurostimulation, and (iii) ketogenic diets (KDs).

Surgical resection appears to be effective in a high percentage (up to 73% are seizure free after 1 year post-surgery) of patients (3, 4). However, surgical intervention could also result in impairment of cognitive functions, such as verbal and visuospatial memory (5). In any case, the surgical approach to pharmacoresistance is a valuable alternative that is warranted when an epileptic focus is clearly identified, whereas in the opposite case alternative treatments, such as intracranial and extracranial neurostimulation and KDs, have to be considered.

Extracranial or intracranial stimulation has been proposed as a possible therapy for refractory epilepsy. In the first case, stimulation is applied to the vagal nerve (6). Recent meta-analyses of the results obtained with vagal stimulation show the limited
We also analyze the changes in endocrine axes related to fasting and ketogenesis or a small patient sample (17). One study was based on various investigations that were limited by the lack of randomization or a small patient sample (17). The clinical efficacy of KDs has been suggested by various investigations that were limited by the lack of randomization or a small patient sample (17). One study was based on the prospective analysis of a large (n = 150) sample of children, aged 1–16 years, with more than two refractory seizures/week, followed for 1 year (18). Interestingly, after 6 months of the KD, 71% remained on the diet, and 51% had a more than 50% decrease in seizure frequency (32% had more than 90% seizure reduction). Similar results were reported by a study that involved 20 children (3–16 years), who were treated for 30 months (19). Positive results were also reported in a controlled randomized study (20). However, limitations of the nutritional approach include adverse effects such as nausea, constipation, abdominal pain, or other less frequent complications (20–22). Low compliance with the dietetic regimen is also frequently present (22). Thus, in the long term effective control of seizures was achieved, at best, in approximately 25% of patients under KDs (21).

Dietetic treatments represent a less invasive approach for managing refractory epilepsy. Moreover, the possibility of understanding how KDs work could be of great help in discovering new treatments with possibly minimal side effects and the ability to control seizures unresponsive to currently available drug treatments. Further achievements may result from the discovery of new mechanisms involved in controlling icotogenesis, when studying the effects of KDs. Until now, the reason why ketogenesis is effective in restraining icotogenesis is undetermined. However, several possible mechanisms have been proposed to contribute to KD effects. This review is aimed at defining the current knowledge on the mechanisms putatively involved in the therapeutic effects of KDs. We also analyze the changes in endocrine axes related to fasting and ketogenesis, to tentatively identify the possible contribution of hormone peptides and neuropeptides to the antiepileptic effects of KDs.

**KD s: COMMON CHARACTERISTICS AND SEVERAL DIFFERENCES**

The classic KD is a low-carbohydrate/high-fat and normal protein diet that has been used as a treatment for pharmacoresistant epilepsy for a long time (22). The classic KD was initially proposed in 1921 (23) and thereafter was used extensively, although it was partially abandoned when AEDs became fully available. In spite of the development of new effective AEDs, the therapeutic application of the classic KD has survived over the decades as an alternative to drug therapy failure (24). During the course of the last 43 years, other modified KDs have been proposed, and the dietetic approach to epilepsy is being reevaluated as an effective alternative to control seizures refractory to at least two different AEDs. The most recently introduced KDs are all aimed at reducing the lipid content of the diet, in order to increase patient compliance and to limit the side effects (22, 25). Interestingly, a common characteristic of all KDs is maintaining a low-carbohydrate content whereas the fat content is presently less stringent (26).

Among the various types of KDs proposed to ameliorate the balance in diet macronutrients, the use of medium chain triglycerides (MCTs) as an alternative fat source was established at the beginning of the 1970s (27). The main constituents of the MCT diet are medium chain octanoic and decanoic fatty acids, which are absorbed more efficiently than long chain fatty acids and are readily transported to the liver by albumin. Conversely, long chain triglycerides (LCTs) are incorporated into chylomicrons and transported via the thoracic duct into the blood circulation. After hepatic uptake, MCTs are rapidly metabolized by liver mitochondria and, following oxidation, converted to ketone bodies. In contrast, LCTs require carnitine as a carrier to enter the mitochondrial biochemical machinery. These differences in metabolism facilitate more rapid and efficient oxidation of MCTs, supposed to result in a higher ketone yield per kilocalorie of dietary energy than that obtained from LCTs. Therefore, less total fat should be required to achieve the desired level of ketosis. With this method, more proteins and higher carbohydrate content may improve palatability and patient acceptance. However, a recent trial that compared the classic KD with the MCT diet demonstrated significantly higher induction of ketone bodies with the classic KD, but the clinical effectiveness of the two alternative diets was the same (21).

In the last few decades, two other types of KDs have been proposed with success. The modified Atkins diet (MAD) was introduced at the John Hopkins Hospital to restrict the fat content of the classic KD by allowing more carbohydrates and, especially, proteins, without limiting the total caloric intake (25). The MAD is based on the popular weight loss diet first described in 1972 (28), which was adapted to allow carbohydrate intake up to a maximum of 10–20 g/day, and by approximating a fat-to-carbohydrate/protein ratio of 1:1, thus less restrictive compared with the 3:1 or 4:1 ratios of the classic KD. Alternatively, the diet known as “low glycemic index treatment” (LGIT) was first described by Pfeifer and Thiele (29). This diet allows carbohydrate intake up to 40–60 g/day using a selection of carbohydrates with a low (<50) glycemic index. Consumption of carbohydrates with a low glycemic index minimizes the increase in glucose blood levels, keeping glycemia at a lower level after the meal. Food is not weighed but given in portion sizes. Protein, fat, and caloric intake under LGIT is considerably less strictly monitored compared with the classic KD. Unlike the MAD, a high-fat intake is not actively encouraged in LGIT protocols (Table 1).
Table 1 | Ketogenic diets (KDs) used to treat pharmacoresistant epilepsy are listed.

| Diet       | Proponent(s) | Fasting Ketogenic ratio | Hospitalization Ketosis | Ketosis (plasma, mmol/L) | Urinary ketones | Fat (%) | Protein (%) | Carbohydrate (%) |
|------------|--------------|-------------------------|-------------------------|--------------------------|-----------------|---------|-------------|------------------|
| Classic KD | Wilder (23)  | Yes                     | Yes                     | 2–4                      | 2–6             | 3–5     | 88–90       | 8                | 2–4              |
| MCT        | Huttenlocher et al. (27) | No                      | 1.3–1.6:1               | 3+–4+                    | 3+–4+          | 70–75   | 10–15       | 15               |
| MAD        | Kossoff et al. (25) | No                      | 0.9:1                   | Not specified            | Variable        | 60–70   | 20–30       | 4–6              |
| LGIT       | Pfeifer and Thiele (29) | No                      | 1:1                     | 0.8–2                    | Variable        | 60–65   | 20–30       | 10–15            |

Note that the ketogenic ratio (fats/carbohydrates–proteins) was progressively decreased by passing the classic KD to the others. Accordingly, a lower ketosis is allowed with diets alternative to classic KD. Fat, proteins, and carbohydrates are indicated in percentages of total calories.

It is clear that varying the amount of carbohydrates in different diets induces different degrees of ketosis. This variability argues against a critical role of ketogenesis in the efficacy of KDs. A recent study by Neal and collaborators (21) compared the therapeutic effects of different levels of ketosis on seizures in a group of 125 children affected by intractable epilepsy. They were randomized to receive the classic KD or the MCT diet. Consistent with previous reports (30), this study showed that the mean acetocetate level was significantly higher in the group maintained on the classic KD in the long term, even after 1 year of treatment, with no differences in the antiepileptic efficacy between the KD and MCT treatments. These data do not support the view of a causal relationship between ketosis and seizure control. Indeed, whereas some authors suggest that ketone bodies must be at a sufficient level to guarantee effective control of seizures (31), others disagree and support the view that a strict link between ketosis and seizure control may be questioned (32, 33). Interestingly, other findings support the hypothesis that a decrease in seizure frequency could depend on a fine balance between glucose reduction and ketone body production (34). Thus, ketosis could be just something more than an epiphenomenon of reduced glucose availability, and this latter could be the major player in controlling seizure activity, common to the different dietetic approaches.

MECHANISMS THOUGHT TO BE INVOLVED IN KD EFFECTS

During the past few decades, interest in understanding the key mechanism of KDs has steadily been grown. Apparently, the mechanisms of KDs could be easily delineated. This alternative therapeutic approach was designed to mimic the biochemical changes associated with fasting, since fasting was proven to be effective in reducing seizure frequency (22, 23, 25). Thus, the reproduction by dietary manipulation of the ketotic state associated with fasting appears to be the way by which pharmaco-resistant epilepsy can be controlled. Ketosis is characterized by increased levels of ketone bodies (β-hydroxybutyric acid, acetoacetic acid, and acetone) that can be achieved by reducing blood glucose levels (35–37). Ketone bodies are the obvious candidates to investigate the mechanism of action by which KDs may control seizure activity. According to Gilbert et al. (31), serum β-hydroxybutyrate levels may correlate with seizure reduction. Although this observation was confirmed by others (38), various studies addressing the anticonvulsant activity of β-hydroxybutyrate failed to demonstrate any relevant effect of this ketone body in different animal models (37, 39–41) or even in vitro (42). However, some investigators demonstrated an anticonvulsant effect of acetacetate and of its metabolite acetone in various seizure paradigms, including the maximal electroshock test, the subcutaneous pentylentetrazole test, the amygdala kindling test, and atypical absence seizures, which characterize the Lennox–Gastaut syndrome (43, 44). Interestingly, acetone may act by opening the two-pore-domain potassium channels (K2p), whose characteristic is to hyperpolarize neurons thus limiting neuronal excitability (45). In spite of these encouraging results, in vivo experimental (46) and clinical studies (47) showed that acetone levels did not rise sufficiently to support the involvement of ketone bodies in the therapeutic effects of KDs. Specifically, according to proton magnetic resonance spectroscopy studies, acetone levels were around 0.7 mM in the brain of patients maintained on a KD (47) or, based on measurements in the cerebrospinal fluid (48), even lower. In addition, the acetone plasma levels effective in rats must be higher than 2 mM; generally, such levels were never obtained under different KD treatments (46). These findings raise several questions: although investigations of animal models remain the required approach for studying the antiepileptic effects of KDs (49, 50), in every tested animal model the efficacy of KDs has strongly depended on the specific seizure model. Moreover, according to some authors, KDs are not effective in seizure models as they are in patients, with the exception of the 6-Hz cortical stimulation paradigm (51, 52) (Table 2).

Inconsistencies between the therapeutic levels of ketone bodies and doses required to produce anticonvulsant activity in vivo and in vitro models are at the basis of the absence of clear explanations of KD effects. Although evidence of the direct involvement of ketone bodies in KD effects is lacking, changes in the functioning of different neurotransmitters have been described in the presence of ketosis and were extensively analyzed in a recent review (37). Relevant changes in γ-aminobutyric acid (GABA) and glycine levels were demonstrated in the cerebrospinal fluid of patients maintained on KDs, suggesting the enhanced activity of inhibitory neurons (62, 63). Conversely, animal studies failed to demonstrate any change in GABA levels measured in the brain homogenates of rodents maintained on a KD, disconfirming a role for GABA in mediating KD effects (64). Although the overall evidence is against upregulation of GABA by KDs in animal models, electrophysiological recordings demonstrated that network excitability is diminished in animals fed with KDs (65). Another hypothesis is based on the depression of glutamatergic transmission (66), since acetacetate and, less efficiently, β-hydroxybutyrate can compete with chloride, which is an allosteric activator of vesicular glutamate transport, and this competition could lead to decreased glutamate release. However, the required concentrations of ketone bodies to
Table 2 | Effects of the ketogenic diet (KD) in seizure and epilepsy models.

| Species | Seizure induction | KD’s effects | Reference |
|---------|-------------------|--------------|-----------|
| Mice    | Bicuculline injection | Reduced seizures | (53) |
| Rat     | Audiogenic seizures | Decreased latency to seizure onset | (54) |
| Rat     | Amygdala kindling | Protection against the focal onset of kindled seizures but not on seizure spread | (55) |
| Rat     | KA injection | Decreased supragranular mossy fiber sprouting | (56) |
| Juvenile mice | Flurthyl test | Protection against mortality | (57) |
| Rat     | MES | More severe seizures | (58) |
| Rat     | PTZ injection | Protection against seizures | (37, 58) |
| Juvenile mice | EL, human idiopathic epilepsy | No effects | (50, 59) |
| Rat pups | PTZ infusion test | Improved survival | (60) |
|         | ECS | Small threshold elevation | |
|         | Maximal PTZ test | No effects | |
|         | Subcutaneous PTZ test | No effects | |
| Juvenile mice | 6-Hz test (corneal) | Marked elevation of the seizure threshold | (51, 52) |
| Mice    | Succinic semialdehyde dehydrogenase/γ-aminobutyric acid deficiency | Increased lifespan | (61) |
|         | | Decreased ataxia | |
|         | | Decreased weight loss | |
|         | | Decreased other abnormalities | |

Notably, the diet is paradoxically proconvulsant in the maximal electroshock stimulation (MES) test, weakly active respectively in the pentylentetrazole (PTZ) test, the kainic acid (KA) model, the electroconvulsive shock (ECS) paradigm, and the flurthyl test, but KD is highly active in the 6-Hz model.

reduce glutamate release appear to be far from those found in patients (37).

A more recent attempt to identify a mechanism for KDs suggested the involvement of $K_{ATP}$ channels, hyperpolarizing ion channels that are opened by low energy levels, i.e., decreased ATP. It has been argued that ketone bodies, which directly enter the Krebs cycle, could reduce glycolytic ATP production thus activating $K_{ATP}$ channels (67). Data obtained in in vitro (68, 69) and in vivo (70) experiments supported the involvement of $K_{ATP}$ channels. However, the evidence that ATP levels are decreased by KDs is lacking (71–73).

Several other mechanisms have been taken into account, including: (i) cerebral acidosis by itself, tentatively reproduced by the administration of inorganic acids (74). However, animal studies have shown that initial acidosis is then compensated and brain pH results are actually normal (75). Another mechanism is (ii) changes in the accumulation of lipids, such as polyunsaturated fatty acids (PUFAs) (76). PUFAs activate the peroxisome proliferator-activated receptor-$\alpha$ and regulate the transcription of genes that enhance energy metabolism (77). The third mechanism is (iii) increased ATP synthesis leading to the accumulation of $K_{ATP}$ channels (78). Adenosine stimulates adenosine A1 receptors and may reduce spontaneous seizures, as shown in mice with elevated levels of adenosine (79). The fourth mechanism is (iv) the noradrenergic tone: noradrenaline may modulate the propensity to develop seizures (80, 81), and KDs were shown to enhance noradrenaline tissue levels. Mice lacking the gene for dopamine β-hydroxylase failed to exhibit an elevated flurthyl threshold when fed a KD (82). An intriguing consequence of KD effects on noradrenergic signaling could be the stimulation of the release of food intake modulators, which are known to work in conjunction with hypothalamic neurotransmitters.

NEW HYPOTHESIS: PEPTIDE HORMONES AS POSSIBLE MEDIATORS OF KD EFFECTS

Several peripheral peptides produced in the gut and associated tissues have been suggested to link changes in body metabolism with central nervous system functions and, thus, may be critical regulators in various pathophysiological conditions, including control of neuronal excitability in epilepsy (83–86). Peptide hormones are short molecules composed of approximately 3–100 amino acid residues, characterized by a structure simpler than that for proteins. Some are also synthesized by neurons and termed neuropeptides. Peptides and neuropeptides act through G-protein coupled receptors diffusely expressed in the nervous system. Notably, neuropeptides can act at a distance by diffusing from the releasing site in the extracellular space to interact with extrasynaptic receptors and produce long-lasting effects (87–89). At least one receptor for each peptide hormone has been identified, which means that presumably several hundred receptors can affect a multitude of intracellular transduction pathways, complicating the interpretation of their functions. Many peptides are expressed in neurons that co-express at least one classic transmitter and often more than one neuropeptide (90, 91). Physiologically, peptides mainly behave as
neuromodulators with prolonged action on multiple physiological and behavioral actions. The long term effects of peptides depend on the modulation of gene expression via activation of a particular cascade of intracellular signaling molecules (92, 93). However, rapid effects of peptides on neuronal activity by interactions among peptide receptors and ion channels or exchangers have also been described (94, 95). The versatility of peptide hormones and neuropeptide actions explains their multiple physiological effects. In line with the localization of neuropeptides in the hippocampus, amygdala, hypothalamus, striatum, and spinal cord, physiological functions include emotional reactivity, learning and memory, neuroendocrine response to stress, hippocampal synaptic plasticity, and hypothalamic neurotransmission (90, 96–98).

**PEPTIDE HORMONES INVOLVED IN THE CONTROL OF METABOLISM**

Metabolism is regulated by various neural and hormonal systems. The latter include hormone peptides that display anorexigenic or orexigenic properties. Peripheral anorexigenic hormones are produced in different tissues, spanning the gut to the pancreas and, finally, including the adipose tissue. Appetite-reducing peptides released by the gut include cholecystokinin (CCK) (99, 100), glucagon-like peptide-1 (GLP-1) (101, 102), peptide YY (PYY) (103, 104), and oxyntomodulin (105, 106). Anorexigenic peptides from the pancreas are the pancreatic polypeptide (PP) (107, 108), glucagon (109), insulin (110, 111), and amylin (112). Finally, hormones that suppress appetite synthesized in the adipose tissue are leptin (113, 114), adiponectin (115), and resistin (116). In contrast to this variety of appetite-suppressing hormones, ghrelin is the only peripheral peptide with orexigenic properties and is mainly produced in the stomach (117, 118). Interestingly, some of the hormones displaying food intake regulatory properties also possess antiseizure effects (86, 119) (Table 3).

The regulation of energy balance depends on the coordination of multiple peripheral and central systems and is tightly modulated by neuropeptides (148, 149). The critical regulation of food intake is thought to occur in the hypothalamus. Neurons in the paraventricular part of the paraventricular hypothalamic nucleus produce the anorectic neuropeptide corticotropin releasing factor (CRF) (150), while those in the lateral hypothalamus produce orexigenic neuropeptides such as orexin and melanin-concentrating hormone (151). The arcuate nucleus of the hypothalamus contains two distinct neuronal populations that produce orexigenic and anorexigenic peptides, which seem to play antagonistic roles in energy balance control and that are regulated by leptin and insulin (152–154). The “anorexigenic” population is located in the lateral subdivision of the arcuate nucleus and produces the anorectic neuropeptides proopiomelanocortin and cocaine- and amphetamine-regulated transcript (155, 156). The “orexigenic” population of neurons is located in the medial subregion of the arcuate nucleus and produces orexigenic neuropeptides such as agouti-related peptide and neuropeptide Y (NPY) (30, 157). The hypothalamic cell groups are specially tuned to sense metabolic changes, to regulate hormonal secretion, energy homeostasis, and metabolism. The mechanisms for controlling food intake during fasting or a KD involve a complex interplay between the peripheral systems controlling gastrointestinal peptide secretion and the central nervous system. These neuronal systems include neuropeptides and peripheral neuroactive peptides such as CRF, opioids, NPY, CCK, orexin, galanin, and leptin, as well as monoamines (serotonin, dopamine, and noradrenaline).

The complex machinery involved in regulating food intake in relation to body metabolism is also strictly linked to the characteristics of the meal. For instance, ghrelin stimulates sugar intake (158), whereas the neuropeptide oxytocin inhibits carbohydrate but not fat intake (159). Galanin, enkephalins (160), and β-endorphin (161) promote the preference for fat meals. Conversely, macronutrients can influence peptide hormone release. This is the case for lipids, which exert a satiating effect that is probably related to the increased secretion of GLP-1, PYY, and CCK (162). Interestingly, in the presence of increased ghrelin levels a high-fat diet can prevent any change in food intake due to hormonal regulation (163). Thus, the classic KD could deeply alter peptide hormone levels and their function by virtue of the prevalent lipid content of the diet. This effect could be further influenced by the presence of ketone bodies or, in some cases, by weight loss. For instance, in the case of weight loss caused by a KD, insulin and leptin are both reduced when compared to pre-diet levels (164). Ghrelin is not affected by weight loss induced by a KD (164), but is increased in the case of anorexia (165, 166) or cachexia (167).

**Table 3 | Changes in different neuroactive peptide levels in animals and humans during various metabolic states, including anorexia, prolonged fasting, or a ketogenic diet (KD).**

| Peptides | Rodents | Reference | Human | Reference |
|----------|---------|-----------|------|----------|
| Leptin   | ↓ KD, fasting | (120, 121) | ↑ ↓ Anorexia, fasting | (122–124) |
| Insulin  | ↓ KD | (125–127) | ↓ KD, anorexia | (124, 128) |
| Adiponectin | ↑ Anorexia, fasting | (129, 130) | ↑ ↓ Anorexia | (131, 132) |
| NPY      | ↑ KD, fasting | (133, 134) | ↓ Anorexia | (122, 135) |
| Galanin  | ↑ KD, fasting | (136) | ↑ Anorexia | (137) |
| Ghrelin  | ↑ KD, anorexia | (138, 139) | ↑ Anorexia, fasting | (140, 141) |
| IGF-1    | ↑ KD | (142) | ↓ Anorexia | (143) |
| CCK      | ↓ Anorexia, KD | (144, 145) | ↑ Anorexia | (146, 147) |

Most studies demonstrated increased adiponectin, neuropeptide Y (NPY), galanin, or ghrelin levels or decreased leptin and insulin levels, in animals and patients exposed to similar conditions. Other abbreviations: CCK, cholecystokinin; IGF-1, insulin-like growth factor 1.
Upregulation of ghrelin levels during the course of starvation is expected, since ghrelin production is stimulated by a negative energy balance as a compensatory response.

**PEPTIDE HORMONES THAT MODULATE SEIZURES**

Peptide hormones and neuropeptides have been extensively investigated in the context of animal models of epilepsy and with clinical studies (Table 4). Lines of evidence point to an important role for peptide hormones and neuropeptides in regulating neuronal activity during seizures. In particular, peptide hormones such as adiponectin, ghrelin, and leptin and neuropeptides such as CCK, galanin, NPY, and somatostatin appear to be promising candidates for future research on new treatments for epilepsy.

Adiponectin is produced by adipocytes to regulate fat oxidation and sensitivity to insulin. Adiponectin plasma levels decreased in metabolic syndrome, suggesting the involvement of this hormone in the insulin resistance and hyperlipidemia characterizing the syndrome (178). Adiponectin knockout (KO) mice developed vascular injury and inflammation when exposed to a high-fat diet. Conversely, adiponectin protected from cerebral ischemia due to modulatory properties on inflammation (179, 180). Beneficial effects were also demonstrated in the kainate model of temporal lobe epilepsy, in which adiponectin reduced neuronal cell loss (176). Lee et al. (177) investigated the effects of kainate administration in adiponectin KO mice fed a high-fat diet, compared with the wild-type (WT) controls, by monitoring the blood parameters related to altered glucose and lipid metabolism, the epileptic response to kainate and acute tissue damage. Although the authors were not able to document the effects of kainate with electroencephalography, the seizure score was always lower in the WT mice compared with the KO mice, which also were characterized by metabolic changes such as glucose intolerance. In another experiment, kainate was directly injected in the hippocampus, and the damage was examined after 2 weeks. Gland reaction was more intense in the adiponectin KO mice compared with the WT mice, but the neuronal cell loss and granule cell dispersion were also significantly more pronounced in the investigated model of metabolic syndrome. These last findings suggest that a high-fat diet causes hippocampal damage in the long term.

Adiponectin receptor were resistant to pilocarpine-induced seizures (119). Conversely, the ghrelin full agonist JMV-1843 failed to prevent pilocarpine-induced seizures (184, 185). Intriguingly, better findings were instead obtained by using ghrelin analogs such as des-acyl ghrelin and EP-80317 (184). Interestingly, des-acyl ghrelin could also modulate other targets through binding to the CD36 scavenger receptor, which is involved in regulating food intake and in signaling cascades that lead to neuronal dysfunction and initiation of cell death (187).

Leptin’s anticonvulsant activity was originally shown in two different models: Xu et al. (188) showed that leptin administered by the intranasal route delayed the effects of the convulsant pentylenetetrazole, as well as reduced seizures evoked by 4-aminopyridine. In addition, the same authors confirmed the anticonvulsant effects of leptin in an *in vitro* model and suggested that this effect was related to the depression of glutamatergic neurotransmission (188). In agreement with these data, pentylenetetrazole-induced seizures were more severe in leptin KO (ob/ob) mice (189). However, at odds with previous findings, other experiments showed that leptin potentiated neocortical electrographic seizures elicited by penicillin, probably by interfering with the production of nitric oxide (190). Leptin’s proconvulsant activity was also suggested by another study (191), in which leptin pretreatment increased the number of animals exhibiting

---

**Table 4 | Changes in the levels of neuroactive peptides following seizures.**

| Peptide | Animal model of epilepsy | Change | Reference |
|---------|---------------------------|--------|-----------|
| NPY     | Electrical kindling        | ↑      | (169)     |
|         | KA model                  |        |           |
| Galanin | KA model                  | ↓      | (170)     |
|         | PTZ model                 |        |           |
| Ghrelin | PTZ model                 | ↓      | (171, 172)|
| CCK     | KA model                  | ↓      | (173, 174)|
|         | Pilocarpine model         |        |           |
| Leptin  | Penicillin model          | ↑      | (172, 175)|
|         | KA model                  |        |           |
| Adiponectin | KA model             | ↓      | (176, 177)|

Note that galanin, ghrelin, cholecystokinin (CCK), and adiponectin decreased, whereas neuropeptide Y (NPY) and leptin levels increased in response to different convulsive stimuli. Other abbreviations: KA, kainic acid; PTZ, pentylenetetrazole.
convulsions in response to N-methyl-D-aspartic acid or kainate administration. Recently, the possible involvement of the cannabinoid CB1 receptor in leptin proconvulsant activity in the penicillin model has also been suggested (175). These discrepancies are still unexplained and could depend on the seizure model. In particular, leptin appears to play a modulatory role rather than to be an anticonvulsant.

The expression of neuropeptides changes dramatically in animal models of epilepsy, especially in the hippocampal formation (Table 4). The implication of these peptides in modulating seizures is likely due to their ability to decrease excitability in the brain. Moreover, their brain concentration changes after spontaneous seizures, and this may contribute to enhanced susceptibility to seizures (169). Importantly, recurrent spontaneous seizures were suppressed by overexpression of NPY in the hippocampus using adeno-associated virus vectors (192). Several studies have investigated the therapeutic potential of these neuropeptides to suppress seizure activity in animals, in various epilepsy models (193). These studies were in agreement with data on NPY or galanin KO mice, which presented an increased propensity to develop seizures (170, 194). Another interesting aspect of neuropeptides is their neuroprotective role after brain injury, a condition that can lead to the development of chronic epilepsy. In particular, NPY promotes neurogenesis in the subventricular zone and the subgranular zone of the adult mouse brain (195, 196). These aspects and others were the focus of recent, extensive reviews about the role of neuropeptides and their receptors (86, 197).

COULD PEPTIDE HORMONES BE MEDIATORS OF KD ANTI-EPILEPTIC EFFECTS?

Patients affected by epilepsy and treated with AEDs present with various changes in the plasma levels of hormones related to metabolism, by which patients could also develop metabolic disorders. In a pioneering study of 40 patients treated with valproate, obesity was found in 15 epileptic patients who also displayed increased leptin and insulin levels and decreased ghrelin and adiponectin levels, when compared with subjects with normal body weight (198). In contrast, another investigation suggested ghrelin production increased (+70%) in patients affected by epilepsy (199). These observations were confirmed by examining the effects of valproic acid treatment on ghrelin in a sample of children characterized by increased body weight, body mass index, and height, in which serum ghrelin levels were higher than in controls and negatively correlated with insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (200). Further studies on ghrelin in patients suffering from epilepsy suggested that ghrelin levels are lower in adults treated with various AEDs (201), as well as in children treated with carbamazepine or valproic acid (202). Finally, a relationship between peptide hormones and seizures has been suggested by a study in which prolactin, nesfatin-1, and ghrelin were evaluated within 5 min after a convolution: the serum levels of prolactin and nesfatin-1 increased, and interestingly, the ghrelin levels were abated for at least 24 h (172). Since ghrelin is a promising candidate in view of its modulatory properties in seizures (119, 203), the changes in this hormone regulation found in patients with epilepsy are of major interest, whereas other changes in peptide hormone regulation, involving leptin, galanin, and NPY (204, 205), must be clearly defined.

The metabolism of peptide hormones such as ghrelin and leptin is modified by seizures and AEDs, suggesting that they could also be affected by KDs. In spite of the important role peptide hormones have in regulating body metabolism (206–208), only a few studies have examined the changes in peptide hormone levels in humans treated with KDs (164, 209, 210). Fraser et al. (209) analyzed the acute anti-inflammatory effects of a KD in patients affected by rheumatoid arthritis and found significant decreases in serum leptin and IGF-1, similar to those observed during acute starvation. These results were probably explained by the weight loss induced by the diet. Significant changes in various peptide hormones associated with weight loss in obese subjects maintained on a KD were also described (164). More interesting for epilepsy and KD treatment, decreased fasting insulin and leptin levels were reported in children affected by Glut-1 deficiency syndrome and treated with a 3:1 KD, whereas adiponectin levels were unmodified (210). In this last study, the observed changes in insulin and leptin levels were not dependent on weight loss. More data have been obtained by studying animal models: Kinzig and collaborators (138) found that rats maintained on a low-carbohydrate/high-fat diet had increased adiposity when compared with controls, accompanied by increased leptin and ghrelin levels and decreased insulin plasma levels. Thus, insulin, but not leptin, was downregulated as in children affected by Glut-1 deficiency syndrome and maintained on KD therapy (210). The high-fat content of the diet seems to be an important requisite to stimulate leptin production, since the leptin levels of rats maintained on a low-carbohydrate/high-fat diet did not vary (211). More interestingly, ghrelin induces ketone bodies production when administered to humans (212), and ghrelin upregulation by a low-carbohydrate/high-fat diet, as demonstrated in rats (138), could be a critical phenomenon in mediating KD effects.

Ghrelin is an important regulator of energy balance that is released from the stomach in response to fasting (180). In addition to regulating appetite, ghrelin stimulates the release of growth hormone (GH) through the GHS-R1a. Other different ghrelin-related peptides are produced in the stomach, including des-acyl ghrelin, which is also obtained by ghrelin desacetylation in the periphery. According to some authors, des-acyl ghrelin represents approximately 90% of total circulating ghrelin-related peptides (213). It regulates the energy balance independently of ghrelin. Indeed des-acyl ghrelin is unable to activate GHS-R1a; thus, this peptide is devoid of GH-releasing properties. Interestingly, fasting alters the secretion of ghrelin and des-acyl ghrelin, but des-acyl ghrelin appears to be a long-lasting signal associated with a negative energy balance. Indeed, when fasting is prolonged and implies a negative energy balance, such as in patients affected by anorexia or cachexia, des-acyl ghrelin is more stably elevated than ghrelin, and the des-acyl ghrelin/ghrelin ratio is also significantly increased (214). Prolonged fasting is mimicked by KD in patients affected by epilepsy. These data suggest that ghrelin-related peptides, especially des-acyl ghrelin, could be stably increased in patients affected by pharmacoresistant epilepsy and receiving a KD treatment. Ghrelin, but not des-acyl ghrelin, modulated the release of GABA via the GHS-R1a receptor (215) and increased the GABAergic
tone. This phenomenon probably explains the counteraction of pentylenetetrazole and penicillin proconvulsive activities observed after ghrelin administration (181, 182). However, des-acyl ghrelin, which does not activate GHS-R1a, also displays anticonvulsive properties by unknown mechanisms, as shown in models of pharmacologically induced acute seizure (184). Experiments based on administration of EP-80317, one of the various molecules developed by modifying ghrelin, confirmed the existence of anticonvulsive effects independent of GHS-R1a receptor activation (203). Des-acyl ghrelin was previously considered an inactive ghrelin metabolite. Although des-acyl ghrelin lacks most of the biological properties of ghrelin, des-acyl ghrelin is now recognized as a hormone because it can modulate food intake by a mechanism independent of GHS-R1a stimulation, depending on circadian rhythmicity and on fasting pre-exposure (216, 217). In addition, des-acyl ghrelin depresses gastrointestinal motility independently of ghrelin, by a central mechanism involving the CRF type 2 receptor (218). At the cellular level, des-acyl ghrelin increased medium chain fatty acid uptake in cardiomiocytes, whereas ghrelin was ineffective; conversely, ghrelin inhibited the increase in glucose uptake normally induced by insulin, but des-acyl ghrelin did not. Thus, des-acyl ghrelin appears to regulate the body metabolism in a way different from ghrelin, without causing dramatic changes in food intake or body development. This hypothesis is confirmed by studies on des-acyl ghrelin transgenic mice that showed a limited decrease in linear growth and slightly reduced fat mass, phenom ena related to the negative energy balance produced by des-acyl ghrelin (219). These properties make des-acyl ghrelin interesting from a pharmacological point of view, also for the nervous system. Pharmacokinetic experiments showed that des-acyl ghrelin enters the brain by non-saturable transmembrane diffusion and is sequestered once within the central nervous system to exert its activity there (218). Thus, the demonstration that des-acyl ghrelin could mediate the anticonvulsive effects of KD could pose the basis for a pharmacological exploitation of this hormone and its possible analogs in epileptic disorders.

Different ghrelin analogs have been developed by simply modifying the peptidergic structure of this hormone, obtaining GH secretagogues with diverse pharmacological profiles (203, 220, 221). Some molecules have been developed to be orally administered and, in general, present an advantageous pharmacokinetic profile when compared with ghrelin. In particular, JMV-1843 is a potent GHS-R1a agonist that stimulates GH release and food intake, whereas JMV-2959 appears to be an antagonist (221, 222). Hexarelin presents less marked GH stimulating properties, which are completely lost with molecules functionally closer to des-acyl ghrelin, such as EP-80317 (187). Interestingly, EP-80317 interacts with CD36 (223), a type B scavenger receptor involved in internalizing oxidized low-density lipoprotein, which initiates a signaling cascade that regulates microglial recruitment and activation, and subsequently, secretion of inflammatory mediators such as interleukin (IL)-1β and IL-6. These mediators, particularly IL-1β, were shown to promote neuronal overexcitation and seizures (224). Indeed, Bulgarelli et al. (187) demonstrated that EP-80317, hexarelin, and des-acyl ghrelin in the nanomolar range effectively counteract the stimulation of IL-1β and IL-6 synthesis in microglial cells lacking the specific ghrelin receptor GHS-R1a, suggesting the involvement of the CD36 receptor in these effects. However, the expression of this receptor in the brain is limited to a few regions (225), and thus, des-acyl ghrelin anticonvulsive effects, whether mediated through CD36 activation, have to be restricted mainly to microglial cells. Thus, new molecular pathways, possibly important for pharmacoresistant epilepsy, could be implicated in des-acyl ghrelin anticonvulsive effects, but these relationships remain to be investigated in appropriate animal models to elucidate their possible involvement in KD beneficial effects.

CONCLUSION

Neuroactive peptides involved in the control of metabolism are putative candidates as mediators of KD effects in pharmacoresistant epilepsy (119, 184). Fasting is mimicked by KDs through inducing ketone bodies and by lowering glucose plasma levels, effects that depend on the activation of some endocrine axis and on the suppression of others. The release of peptides such as insulin, leptin, ghrelin, des-acyl ghrelin, and adiponectin is closely related to food intake or fasting. These hormones have also been related to seizure induction (insulin) or suppression (leptin, ghrelin, des-acyl ghrelin, and adiponectin). Thus, several peripherally originated neuroactive peptides could play a role in modulating epileptic activity in the brain, and their changes in response to fasting or KDs are of primary interest in the attempt to clarify which mechanism could be responsible for the efficacy of dietetic approaches to pharmacoresistant epilepsy. A promising hormonal product is represented by des-acyl ghrelin. This neuroactive peptide is increased in catabolic states and was shown to exert anticonvulsant activity in models of SE (184). A des-acyl ghrelin analog, EP-80317, was also effective in preventing seizure induction by pilocarpine when preventively administered in rats (203). In future studies, we suggest that des-acyl ghrelin may deserve thorough investigation as a possible mediator of KD effects.

Identifying KD mediators could represent a significant advancement in treating pharmacoresistant epilepsy. Although patients suffering from pharmacoresistance could take advantage of therapeutic alternatives such as surgical resection of epileptic foci, intracranial or extracranial neural stimulation, or KDs, compliance with these approaches is not optimal. Many reasons could discourage a patient from adopting any of these therapeutic alternatives to drug treatment: (i) the need for invasive surgery; (ii) possible impairment of cognitive and memory functions caused by intracranial or extracranial stimulation; and (iii) gastrointestinal complications related to KDs such as nausea, constipation, and abdominal pain. Clarification of the neuronal and molecular mechanisms of antiepileptic effects of KDs will propose a specific therapeutic solution for pharmacoresistant epilepsy.

ACKNOWLEDGMENTS

This study was supported by the Italian Ministry of Health (grant RF-2010-2309921 to Giuseppe Biagini).

REFERENCES

1. Berg AT, Beca CB, Loddenkemper T, Vickrey BG, Dlugos D. Priorities in pediatric epilepsy research: improving children’s futures today. Neurology (2013) 81:1166–75. doi:10.1212/WNL.0b013e3182a551f9
2. Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. *Lancet Neurol* (2007) 6:793–804. doi:10.1016/S1474-4422(07)70215-6

3. Wiebe S, Blume WT, Girvin JP, Eliazyiz M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. *N Engl J Med* (2001) 345:311–8. doi:10.1056/NEJM20010823450501

4. Lim ME, Bowen JM, Snead OC, Elliott I, Donner E, Weiss SK, et al. Access to care for pediatric patients with medically refractory epilepsy: a systems analysis. *Epilepsy Res* (2013) 107:286–96. doi:10.1016/j.epleyr.2013.08.010

5. Engel Jr, McDermott MP, Wiebe S, Langfit JT, Stern JM, Dewar S, et al. Early surgical therapy for drug-resistant temporal-lobe epilepsy: a randomized trial. *JAMA* (2012) 307:922–30. doi:10.1001/jama.2012.220

6. Schachter SC, Saper CB. Vagus nerve stimulation. *Epilepsia* (1998) 39:767–86. doi:10.1111/j.1528-1157.1998.tb01151.x

7. Parker AP, Polkey CE, Binnie CD, Madigan C, Ferrie CD, Robinson BO. Vagal nerve stimulation in epileptic encephalopathies. *Pediatrics* (1999) 103:778–82. doi:10.1542/peds.103.7.477

8. Carius A, Wintermantel A. Vagus nerve stimulation therapy in epilepsy patients: long-term outcome and adverse effects: a retrospective analysis. *Nervenarzt* (2013) 84:1473–85. doi:10.1007/s00115-013-3923-4

9. Klinkenberg S, van den Bosch CN, Majoie HC, Balbers MW, Leenen L, Hendriksen J, et al. Functional and cognitive effects during vagus nerve stimulation in children with intractable epilepsy – a randomized controlled trial. *Eur J Paediatr Neurol* (2013) 17:82–90. doi:10.1016/j.ejpn.2012.07.003

10. Morris IMGL, Gloss D, Buchhalter J, Mack JK, Nicks K, Harden C. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy. *Neurology* (2013) 81:453–9. doi:10.1212/01.wnl.0000187071.24292.9e

11. Skarpaas TL, Morrell MJ. Intracranial stimulation therapy for epilepsy. *Neurology* (2005) 65:1810–2. doi:10.1212/01.wnl.0000187071.24292.9e

12. Levy RG, Cooper PN, Giri P. Ketogenic diet and other dietary treatments based guideline update: vagus nerve stimulation for the treatment of epilepsy. *Epilepsia* (2013) 54:291–301. doi:10.1111/j.1528-1167.2012.00438.x

13. Chapman KE, Kim DY, Rho JM, Ng YT, Kerrigan ME, Jenning KE. Ketogenic diet in the treatment of seizures associated with hypothalamic hamartomas. *Epilepsia* (2011) 52:4218–21. doi:10.1111/j.1365-2947.2011.02345.x

14. Huttonlocher PR, Wilbourn AJ, Signore JM. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. *Neurology* (1971) 21:1097–103. doi:10.1212/01.wnl.0000187071.24292.9e

15. Atkins RC, Dr. Atkins’ New Diet Revolution. New York, NY: David McKay Inc Publishers (1972).

16. Pfeifer HH, Thiele EA. Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy. *Neurology* (2005) 65:1810–2. doi:10.1212/01.wnl.0000187071.24292.9e

17. Schwartz MW, Woods SC, Porte DJ, Seeley RJ, Baskin DG. Central nervous system control of food intake. *Nature* (2000) 404:661–71. doi:10.1038/35007534

18. Gilbert DL, Pyzik PL, Freeman JM. The ketogenic diet: seizure control correlates better with serum β-hydroxybutyrate than with urine ketones. *J Child Neurol* (2000) 15:787–90. doi:10.1177/088307380001501203

19. Bougie KJ, Matthews PJ, Eagles DA. A ketogenic diet has different effects upon seizures induced by maximal electroshock and by pentyleneetetrazole infusion. *Epilepsy Res* (2000) 38:105–14. doi:10.1016/S0920-1211(99)00079-0

20. Seo JH, Lee YM, Lee JS, Kang HC, Kim HD. Efficacy and tolerability of the ketogenic diet according to lipid/nondlipid ratios-comparison of 3:1 with 4:1 diet. *Epilepsia* (2007) 48:801–5. doi:10.1111/j.1528-1167.2007.01025.x

21. Seyfried TN, Mantis JG, Todorova ME, Greene AE. Ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. *Pediatrics* (2004) 113:2007–14. doi:10.1542/peds.105.4.e46

22. Rho JM, White HS, Anderson G, Donevan S. Acetoacetate, acetone, and dibenzoyl methane are not dependent on its metabolites acetol, 1,2-propanediol, methylglyoxal, or pyruvic acid. *Ann Neurol* (2002) 52:391–7. doi:10.1002/ana.10363

23. Wilder RM. The effects of ketonemia on the course of epilepsy. *Mayo Clin Proc* (1921) 2:307–8.

24. Stafstrom CE. Dietary approaches to epileptic treatment: old and new options on the menu. *Epilepsy Curr* (2004) 4:215–22. doi:10.1111/j.1528-7597.2004.4601.x

25. Kostoff EH, McGrogan JR, Bluml RM, Pillas DJ, Rubenstein JE, Vining EP. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. *Epilepsia* (2006) 47:421–4. doi:10.1111/j.1528-1167.2006.00438.x

26. Chapman KE, Kim DY, Rho JM, Ng YT, Kerrigan ME, Jenning KE. Ketogenic diet in the treatment of seizures associated with hypothalamic hamartomas. *Epilepsia* (2011) 52:4218–21. doi:10.1111/j.1365-2947.2011.02345.x

27. Giordano et al. Ketogenesis and neuropeptides

www.frontiersin.org

April 2014 | Volume 5 | Article 63 | 9
45. Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. *Epilepsia* (2007) 48:43–58. doi:10.1111/j.1528-1167.2007.00915.x

46. Nylen K, Likhodii SS, Hum KM, Burnham WM. A ketogenic diet and diallyl sulfide do not elevate afterdischarge thresholds in adult kindled rats. *Epilepsy Res* (2006) 71:23–31. doi:10.1016/j.eplepsyres.2006.05.008

47. Seymour KJ, Bluml S, Sutherling W, Ross BD. Identification of cerebral acetone by 1H-MRS in patients with epilepsy controlled by ketogenic diet. *MAGMA* (1999) 8:33–42. doi:10.1007/BF02590633

48. Nordli DR Jr, De Vivo DC. The ketogenic diet revisited: back to the future. *Epilepsia* (1997) 38:743–9. doi:10.1111/j.1528-1167.1997.tb01460.x

49. Wada K, Kiryu K, Kawata Y, Chiba T, Mizuno K, Okada M, et al. Prognosis and clinical features of intractable epilepsy: a prospective study. *Psychiatry Clin Neurosci* (1997) 51:233–5. doi:10.1111/j.1440-1819.1997.tb25890.x

50. Todorova MT, Tandon P, Madore RA, Stafstrom CE, Seyfried TN. The ketogenic diet effects on audiogenic seizures susceptibility of magnesium deficient rats. *Pharmacol Biochem Behav* (1983) 18:683–7. doi:10.1016/0091-3057(83)90060-6

51. Hartman AL, Gasior M, Vining EPG, Rogawski MA. The neuropharmacology of the ketogenic diet. *Pediatr Neurol* (2007) 36:281–92. doi:10.1016/j.pediatrneurol.2007.02.008

52. Hartman AL, Lyle M, Rogawski MA, Gasior M. Efficacy of the ketogenic diet in the 6-Hz seizure test. *Epilepsia* (2008) 49:334–9. doi:10.1111/j.1528-1167.2007.01430.x

53. Uhlemann ER, Neims AH. Anticonvulsant properties of the ketogenic diet in mice. *J Pharmacol Exp Ther* (1972) 180:231–8.

54. Mahoney AW, Hendricks DG, Bernhard N, Sisson DV. Fasting and ketogenic diet effects on audiogenic seizures susceptibility of magnesium deficient rats. *Pharmacol Biochem Behav* (1983) 15:507–24. doi:10.1016/0091-3057(83)90060-6

55. Hori A, Tandon P, Holmes GL, Stafstrom CE. Ketogenic diet: effects on expression of kindled seizures and behavior in adult rats. *Epilepsia* (1997) 38:750–8. doi:10.1111/j.1528-1167.1997.tb01461.x

56. Muller-Schwarze AB, Tandon P, Liu Z, Yang Y, Holmes GL, Stafstrom CE. Ketogenic diet reduces spontaneous seizures and mossy fiber sprouting in the kainic acid model. *Neuroreport* (1999) 10:1517–22. doi:10.1097/00001209-199905140-00023

57. Rho JM, Kim DW, Robbins CA, Anderson GD, Schwartzkroin PA. Age-dependent differences in flurothyl seizure sensitivity in mice treated with a ketogenic diet. *Epilepsia* (1999) 40:233–40. doi:10.1111/j.1528-1167.1999.00068-6

58. Rho KJ, Eagles DA. A ketogenic diet increases the resistance to audiogenic seizures of magnesium deficient rats. *Neurology* (2011) 77:507–14. doi:10.1212/01.wnl.0000391824.92551.95

59. Nylen K, Likhodii S, Burnham WM. The ketogenic diet: proposed mechanisms of action. *Neurotherapeutics* (2009) 6:402–5. doi:10.1007/s13311-009-0041-7

60. Lennox WG, Cobb S. Studies in epilepsy VIII. The clinical effect of fasting. *Arch Neurol Psychiatry* (1928) 20:771–9. doi:10.1001/archneurpsyc.1928.021101102899.

61. Al-Mudallal AS, Al-Mudallal AS, Blaise BH. A ketogenic diet reduces long-term potentiation in the dentate gyrus of freely behaving rats. *J Neurophysiol* (2011) 106:662–6. doi:10.1152/jn.00001.2011

62. DeVivo DC, Leckie MP, Ferrendelli JS, McDeugul DB. Chronic ketosis and cerebral metabolism. *Ann Neurol* (1978) 3:331–7. doi:10.1002/ana.4100341010

63. Bough KJ, Wetherington J, Hassel B, Pare PG, Gawryluk JW, Greene JG. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. *Ann Neurol* (2006) 60:223–35. doi:10.1002/ana.20899

64. Nylen K, Likhodii S, Burnham WM. The ketogenic diet: proposed mechanisms of action. *Neurotherapeutics* (2009) 6:402–5. doi:10.1007/s13311-009-0041-7

65. Lennox WG, Cobb S. Studies in epilepsy VIII. The clinical effect of fasting. *Arch Neurol Psychiatry* (1928) 20:771–9. doi:10.1001/archneurpsyc.1928.021101102899.

66. Vanecek J, Valle J, Lesage F, Greissen P, Dables J. Antiepileptic popular ketogenic diet: emerging twists in an ancient story. *Prog Neurobiol* (2005) 75:1–28. doi:10.1016/j.pneurobio.2004.11.003

67. Cullingford TE. The ketogenic diet: fatty acids, fatty acid-activated receptors and neurological disorders. *Prostaglandins Leukot Essent Fatty Acids* (2004) 70:253–64. doi:10.1016/j.plefa.2003.09.008

68. Masino SA, Sejer JD. Are purines mediators of the anticonvulant/ neuroprotective effects of ketogenic diets? *Trends Neurosci* (2008) 31:273–8. doi:10.1016/j.tins.2008.02.009

69. Masino SA, Theofilas P, Li T, Ruskin DN, Fredholm BB, Gejer JD, et al. A ketogenic diet suppresses seizures in mice through adenosine A1 receptors. *J Clin Invest* (2011) 121:2679–83. doi:10.1172/JCI57813

70. Giorgi FS, Pizzanelli C, Biagioni F, Murri L, Fornai F. The role of norepinephrine in epilepsy: from the bench to the bedside. *Curr Med Chem* (2011) 18(37):5072–24. doi:10.2174/0929867320666131119154018

71. Tapper M, Madsen EM, Ingleby B, Aabo Sorensen P, Eklund J, et al. Gene therapy for epilepsy. *Epilepsy Behav* (2011) 21:179–83. doi:10.1016/j.yebeh.2010.10.011

72. Hökfelt T, Mutt V. Neuropeptides. In: Adelman G, Smith BH, editors. *The Encyclopedia of Neuroscience*. Vol. 2. Amsterdam: Elsevier (1999), p. 1423–9.

73. DeWied D, Siglig H. Neuropeptides involved in the pathophysiology of schizophrenia and major depression. *Neurotox Res* (2002) 4:453–68. doi:10.1007/s12640-002-0040-2

74. Simonato M. Gene therapy for epilepsy. *Epilepsy Behav* (2014). doi:10.1016/j.yebeh.2013.09.013

75. Dobolyi A, Kekesi KA, Juhasz G, Szekely AD, Lovas G, Kovacs Z. Receptors of peptides as therapeutic targets in epilepsy research. *Curr Med Chem* (2014) 21:764–87. doi:10.2174/1022150413666131119154018

76. Agnati LF, Cortelli P, Biagini G, Bjelke B, Fuxe K. Different classes of volume transmission signals exist in the central nervous system and are affected by metabolic signals, temperature gradients and pressure waves. *Neuroreport* (1994) 6:99–12. doi:10.1097/00001756-199412000-00004

77. Ludwig M, Leng G. Dendritic peptide release and peptide-dependent behaviours. *Nat Rev Neurosci* (2006) 7:126–36. doi:10.1038/nrn1845
101. Flint A, Raben A, Astrup A. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Nutr (2006) 136:2006–12. doi:10.1093/jn/136.12.2006

102. Little TJ, Horowitz M, Feinle-Bisset C. Role of cholecystokinin in appetite control and body weight regulation. Obes Rev (2005) 6:297–306. doi:10.1111/j.1467-789X.2005.00212.x

103. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Patterson M, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab (2003) 88:4606–50. doi:10.1210/jc.2003-030421

104. Dabin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, et al. Peptidase–protein peptidase reduces appetite and food intake in humans. J Clin Endocrinol Metab (2003) 88:3989–92. doi:10.1210/jc.2003-030630

105. Hankir MK, Parkinson JR, Minnion JS, Addison ML, Bloom SR, Bell JD. Peptide YY 3–36 and pancreatic polypeptide differentially regulate hypothalamic neuronal activity in mice in vivo as measured by manganese-enhanced magnetic resonance imaging. J Neuroendocrinol (2011) 23:371–80. doi:10.1111/j.1365-2826.2011.0211

106. Giordano et al. Ketogenesis and neuropeptides

107. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, et al. Effects of the ketogenic diet on plasma adiponectin levels in patients with anorexia nervosa examined in anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab (2011) 96:1833–40. doi:10.1210/jc.2010-301126

108. Tabb K, Sztot P, White SS, Liles LC, Weinshenker D. The ketogenic diet does not alter brain expression of orexigenic neuropeptides. Epilepsy Res (2004) 62:58–69. doi:10.1016/j.eplepsyres.2004.08.002

109. Tallent MK. Presynaptic inhibition of glutamate release by neuropeptides: use-dependent synaptic modification. Results Probl Cell Differ (2008) 44:177–200. doi:10.1007/978-0-300-1207_03

110. Fujie K, Li XM, Bjelke B, Hedlund PB, Biagini G, Agnati LF. Possible mechanisms for the powerful actions of neuropeptides. Ann NY Acad Sci (1994) 739:42–59. doi:10.1111/j.1749-6632.1994.tb18906.x

111. Hökfelt T, Broberger C, Xu ZQ, Sergeyev V, Ubink R, Diez M. Neuropeptides – an overview. Neuropharmacology (2000) 39:1337–56. doi:10.1016/s0028-3908(00)00010-1

112. Clime MA, Mandar W, Smith ML, Pittman BH, Kelly M, Rogers JY. Amylin causes anorexigenic effects via the hypothalamus and brain stem in chicks. Regul Pept (2008) 146:140–6. doi:10.1016/j.regpep.2007.09.003

113. Fulton S, Woodside B, Shigal P. Modulation of brain reward circuitry by leptin. Science (2000) 287:125–8. doi:10.1126/science.287.5450.125

114. Schwartz MW. Central nervous system regulation of food intake. Obesity (2006) 14(Suppl 1):1–85. doi:10.1038/oby.2006.275

115. Qyi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Papain UB, et al. Adiponectin acts in the brain to decrease body weight. Nat Med (2014) 10:524–9. doi:10.1038/nm.3109

116. Tovar S, Nogueiras R, Tung YL, Castañeda TR, Vázquez MJ, Morris A, et al. Central administration of resistin promotes short-term satiety in rats. Eur J Endocrinol (2005) 153:R1–R5. doi:10.1530/eje.1.01999

117. Wren AM, Seal LJ, Cohen MA, Bynes AE, Frost GS, Murphy KG, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab (2001) 86:5992–5. doi:10.1210/jc.86.12.5992

118. Naleid AM, Grace MK, Cummings DE, Levine AS. Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens. Peptides (2005) 26:2274–9. doi:10.1016/j.peptides.2005.04.025

119. Portelli J, Michotte Y, Smolders I. Ghrelin: an emerging new anticonvulsant neuropeptide. Epilepsia (2012) 53:585–95. doi:10.1111/j.1365-2826.2012.03423

120. Kimzig KP, Taylor RJ. Maintenance on a ketogenic diet: voluntary exercise, adiposity and neuroendocrine effects. Int J Obes (2009) 33:824–30. doi:10.1038/ijo.2009.109

121. Ahima RS, Prabakaran D, Mantorzos C, Qu D, Lowell B, Maratos-Flier E, et al. Role of leptin in the neuroendocrine response to fasting. Nature (1996) 382:250–2. doi:10.1038/382250a0

122. Ostrowskima J, Ziese K, Geisler G, Broll-Waska K. Prospective evaluation of leptin and neuropeptide Y (NPY) serum levels in girls with anorexia nervosa. Neurol Endocrin Lett (2005) 26:301–4.

123. Monteleone P, Castaldo E, Maj M. Neuroendocrine dysregulation of food intake in eating disorders. Regul Pept (2008) 149:39–50. doi:10.1016/j.regpep.2007.10.007

124. Hayes MR, Miller CK, Ulbeccht JS, Mauger JL, Parker-Klees L, Gutschall MD, et al. A carbohydrate–restricted diet alters gut peptides and adiposity signals in men and women with metabolic syndrome. J Nutr (2007) 137:1944–50.

125. Thiis EL, Erbayat–Altay E, Rensing N, Yamada KA. Leptin contributes to slower weight gain in juvenile rodents on a ketogenic diet. Pediatr Res (2006) 60:413–7. doi:10.1203/pdr.012003.pdr.00283.h44.5106.27

126. Honors MA, Davenport BM, Kimzig KP. Effects of consuming a high carbohydrate–diet diet after eight weeks of exposure to a ketogenic diet. Nutr Metab (2009) 6:46. doi:10.1186/1743-7075-6-46

127. Badman MK, Kennedy AR, Adams AC, Pissios P, Maratos-Flier E. A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss. Am J Physiol Endocrinol Metab (2009) 297:E1197–204. doi:10.1152/ajpendo.00357

128. Ferry F, Bouchet P, Christophe J, Balasse EO. Hormonal and metabolic changes induced by an isocaloric isoproteic ketogenic diet in healthy subjects. Diabete Metab (1982) 8:299–305.

129. Brichard SM, Delporte ML, Lambert M. Adipocytokines in anorexia nervosa: a review focusing on leptin and adiponectin. Horm Metab Res (2005) 37:337–42.

130. Chaolu H, Asakawa A, Ushikai M, Li YX, Cheng KC, Li JB. Effect of exercise and high-fat diet after eight weeks of exposure to a ketogenic diet. J Nutr (2009) 139:140–6. doi:10.1038/00239.003

131. Tabb K, Szot P, White SS, Liles LC, Weinshenker D. The ketogenic diet does not alter brain expression of orexigenic neuropeptides. Diabetes Res Clin Pract (2004) 62:58–69. doi:10.1016/j.eplepsia.2004.08.002

132. Tagami T, Satoh N, Usui T, Yamada K, Shimatsu A, Kurisu Y. Adiponectin in anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab (2004) 89:1833–7. doi:10.1210/jc.2003-031260
from lesions to leptin: hypothalamic control

Leptin and insulin pathways in POMC and AgRP neurons.

Altered hypothalamic signaling and responses to food deprivation in rats fed a low-carbohydrate diet. Obes Res (2005) 13:1672–82. doi:10.1038/oby.2005.205

Incomplete restoration of the secretion of ghrelin and PYY compared to insulin after food ingestion following weight gain in anorexia nervosa. J Psychosom Res (2007) 61:814–20. doi:10.1016/j.jpsychores.2006.07.021

Increased circulating cholecystokinin concentrations in anorexia nervosa on a high fat diet. Eur J Pharmacol (2013) 697:6276–81. doi:10.1016/j.ejphar.2013.06.019

Increased ghrelin and obestatin levels before and after a meal in children with simple obesity and anorexia. J Clin Endocrinol Metab (2014) 99:1068–70. doi:10.1210/jc.2013-4051

Peripheral ghrelin enhances sweet taste food consumption and preference, regardless of its caloric content. Physiol Behav (2010) 101:277–81. doi:10.1016/j.physbeh.2010.05.017

Peripheral ghrelin enhances sweet taste food consumption and preference, regardless of its caloric content. Physiol Behav (2010) 101:277–81. doi:10.1016/j.physbeh.2010.05.017

Effects of galanin on growth hormone and prolactin secretion in anorexia nervosa. Metabolism (2010) 61:1182–7. doi:10.1016/j.metabol.2010.02.011

The hyperphagic effect of ghrelin is inhibited in mice by a diet high in fat. Gastroenterology (2010) 138:2468–76. doi:10.1053/j.gastro.2010.02.012

Ketosis and appetite-mediating nutrients and hormones after weight loss. Eur J Clin Nutr (2013) 67:759–64. doi:10.1038/ejcn.2013.90

Changes in ghrelin and obestatin levels before and after a meal in children with simple obesity and anorexia. J Clin Endocrinol Metab (2014) 99:1068–70. doi:10.1210/jc.2013-4051

Gall C. Seizures induce dramatic and distinctly different changes in enkephalin, dynorphin, and CCK immunoreactivities in mouse hippocampal mossy fibers. J Neurosci (1988) 8:1852–62.

Weyth MS, Zhang N, Mody I, Houser CR. Selective reduction of cholecystokinin-positive basket cell innervation in a model of temporal lobe
epilepsy. *J Neurosci* (2010) 30:8993–9006. doi:10.1523/JNEUROSCI.1183-10.2010

175. Arslan G, Aliko SK, Aydildiz M, Agar E. The role of CB1-receptors in the proconvulsant effect of leptoic on penicillin-induced epileptiform activity in rats. *CNS Neurosci Ther* (2013) 19:222–8. doi:10.1111/cns.12075

176. Jeon BT, Shin HJ, Kim JB, Kim YK, Lee DH, Kim KH, et al. Adiponectin protects hippocampal neurons against kainic acid-induced excitotoxicity. *Brain Res Rev* (2009) 61:81–8. doi:10.1016/j.brainres.2009.05.002

177. Lee EB, Warmann G, Dhir R, Ahima RS. Metabolic dysfunction associated with adiponectin deficiency enhances kainic acid-induced seizure severity. *J Neurosci* (2011) 31:14363–6. doi:10.1523/JNEUROSCI.3171-11.2011

178. Girola SA. Metabolic actions of adipocytokines: focus on adiponectin. *Obesity* (2006) 14(Suppl 1):95–155. doi:10.1038/oby.2006.276

179. Nishinuma M, Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C, et al. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. *Circulation* (2008) 117:216–23. doi:10.1161/CIRCULATIONAHA.107.702544

180. Chen B, Liao WQ, Xu N, Xu H, Wen JY, Yu CA, et al. Adiponectin protects against cerebral ischemia-reperfusion injury through anti-inflammatory action. *Brain Res* (2009) 1273:129–37. doi:10.1016/j.brainres.2009.04.002

181. Obsay BD, Tasdemir E, Tumer C, Bilgin HM, Sermet A. Antiepileptic effects of ghrelin on pentenylenetetrazole-induced seizures in rats. *Peptides* (2007) 28:1214–9. doi:10.1016/j.peptides.2007.04.003

182. Aslan A, Yildirim M, Aydildiz M, Guven A, Ege A. The role of nitric oxide in the inhibitory effect of ghrelin against penicillin-induced epileptiform activity in rat. *Neuropeptides* (2009) 49:295–302. doi:10.1016/j.neupd.2009.05.005

183. Lee J, Lim E, Kim VJ E, Park S. Ghrelin attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. *J Endocrinol* (2010) 205:263–70. doi:10.1677/JEO-10-00440

184. Biagini G, Torsello A, Marinelli C, Gualtieri F, Vezzali R, Cocco S, et al. Beneficial effects of desacyl-ghrelin, hexarelin and EP-80317 in models of status epilepticus. *J Pharmacol* (2011) 60:130–6. doi:10.1002/jph.2011.08.020

185. Lucchi C, Curia G, Vinet J, Gualtieri F, Bresciani E, Locatelli V, et al. Protective but not anticonvulsant effects of ghrelin and JMIV-184 in the pilocarpine model of status epilepticus. *Plos One* (2013) 8(6):e27216. doi:10.1371/journal.pone.0027216

186. Giorgio B, Locatelli V, Torsello A. Ghrelin anticonvulsive properties: is it a matter of desaclyation? *Epilepsia* (2012) 53:1277–84. doi:10.1111/j.1528-1167.2012.03546.x

187. Bulgarelli I, Tamiazzo L, Bresciani E, Rapetti D, Caporali S, Lattuada D, et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. *Neurosci Lett* (2003) 311:17–21. doi:10.1016/S0728-8875(02)01809-7

188. Xu L, Rensing N, Yang XF, Zhang HX, Thio LL, Rothman SM, et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. *Neurosurgery* (2004) 54:527–31. doi:10.1093/neuros/54.4.527

189. Berilgen MS, Mungen B, Ustundag B, Demir C. Serum ghrelin levels are enhanced in patients with epilepsy. *Seizure* (2006) 15:106–11. doi:10.1016/j.seizure.2005.11.008

190. Apriglian MS, Mungen B, Ustundag B, Demir C. Serum ghrelin levels are enhanced in patients with epilepsy. *Seizure* (2006) 15:106–11. doi:10.1016/j.seizure.2005.11.008

191. Agasse F, Bernardino L, Kristiansen H, Christiansen SH, Ferreira R, Silva B, et al. Neuropeptide Y promotes neurogenesis in murine subventricular zone. *Stem Cells* (2008) 26:1636–45. doi:10.1663/stemcells.2008-0056

192. Kovac S, Walker MC. Neuropeptides in epilepsy. *Neuropeptides* (2013) 47:667–75. doi:10.1016/j.npept.2013.10.015

193. Greco R, Latini G, Chierelli F, Iannetti F, Verrotti A, Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. *Neurology* (2005) 65:13808–9. doi:10.1212/01.wnl.0000187074.27586.d1

194. Howell OW, Silva AA, Scharfman HE, Susonov AA, Zaben M, Shatya A, et al. Neuropeptide Y is important for basal and seizure-induced precursor cell proliferation in the hippocampus. *Neurobiol Dis* (2007) 26:174–88. doi:10.1016/j.nbd.2006.12.014

195. Agasse F, Bernardino L, Kristiansen H, Christiansen SH, Ferreira R, Silva B, et al. Neuropeptide Y promotes neurogenesis in murine subventricular zone. *Stem Cells* (2008) 26:1636–45. doi:10.1663/stemcells.2008-0056

196. Agasse F, Bernardino L, Kristiansen H, Christiansen SH, Ferreira R, Silva B, et al. Neuropeptide Y promotes neurogenesis in murine subventricular zone. *Stem Cells* (2008) 26:1636–45. doi:10.1663/stemcells.2008-0056

197. Kovac S, Walker MC. Neuropeptides in epilepsy. *Neuropeptides* (2013) 47:667–75. doi:10.1016/j.npept.2013.10.015

198. Greco R, Latini G, Chierelli F, Iannetti F, Verrotti A, Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. *Neurology* (2005) 65:13808–9. doi:10.1212/01.wnl.0000187074.27586.d1

199. Berilgen MS, Mungen B, Ustundag B, Demir C. Serum ghrelin levels are enhanced in patients with epilepsy. *Seizure* (2006) 15:106–11. doi:10.1016/j.seizure.2005.11.008
laminae of mouse spinal cord dorsal horn. Endocrinology (2008) 149:2306–12. doi:10.1210/en.2007-1164
216. Toshinai K, Yamaguchi H, Sun Y, Smith RG, Yamanaka A, Sakurai T, et al. Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology (2006) 147:2306–14. doi:10.1210/en.2005-1357
217. Inhoff T, Wiedenmann B, Klapp BF, Monnikes H, Kobelt P. Is desacyl ghrelin a modulator of food intake? Peptides (2009) 30:991–4. doi:10.1016/j.peptides.2009.01.019
218. Chen CY, Inui A, Asakawa A, Fujino K, Kato I, Chen CC, et al. Des-acyl ghrelin acts by CRF type 2 receptors to disrupt fasted stomach motility in conscious rats. Gastroenterology (2005) 129:8–25. doi:10.1053/j.gastro.2005.04.015
219. Iwakura H, Hosoda K, Son C, Fujikura J, Tomita T, Noguchi M, et al. Analysis of rat insulin II promoter-ghrelin transgenic mice and rat glucagon promoter-ghrelin transgenic mice. J Biol Chem (2005) 280:15247–56. doi:10.1074/jbc.M411358200
220. Guerlavais V, Boeglin D, Mousseaux D, Oiry C, Heitz A, Deghenghi R, et al. New active series of growth hormone secretagogues. J Med Chem (2003) 46:1191–203. doi:10.1021/jm020985q
221. Moulin A, Demange L, Ryan J, Mousseaux D, Sanchez P, Bergé G, et al. New tri-substituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations. J Med Chem (2008) 51:689–93. doi:10.1021/jm070129z
222. Demange L, Boeglin D, Moulin A, Mousseaux D, Ryan J, Bergé G, et al. Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor. 1. J Med Chem (2007) 50:1939–57. doi:10.1021/jm070024h
223. Demers A, McNicoll N, Febbraio M, Servant M, Marleau S, Silverstein R, et al. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J (2004) 382:417–24. doi:10.1042/Bj0400306
224. Balosso S, Maroso M, Sanchez-Alavez M, Ravizza T, Frasca A, Bartfai T, et al. A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1β. Brain (2008) 131:3256–65. doi:10.1093/brain awn271
225. Glezer I, Bittencourt JC, Rivest S. Neuronal expression of Cd36, Cd44, and Cd83 antigen transcripts maps to distinct and specific murine brain circuits. J Comp Neurol (2009) 517:906–24. doi:10.1002/cne.22185

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 19 March 2014; paper pending published: 09 April 2014; accepted: 14 April 2014; published online: 29 April 2014.

Citation: Giordano C, Marchio M, Timofeeva E and Biagini G (2014) Neuroactive peptides as putative mediators of antiepileptic ketogenic diets. Front. Neurol. 5:63. doi: 10.3389/fneur.2014.00063

This article was submitted to Epilepsy, a section of the journal Frontiers in Neurology. Copyright © 2014 Giordano, Marchio, Timofeeva and Biagini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.